Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Sera Prognostics, Inc.NASDAQ: SERA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $42K rose 5.0% year over year, behind the +58.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Cost of revenue amounted to 202.5% of revenue in FY2025, up 96.0 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +5.0% toward the trailing-twelve-month pace of +58.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$42K+0.0% QoQ
Last fiscal yearDec 2025
$164K+100.0% YoY
LTMMar 2026
$166K+58.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.0%——
1 year+100.0%——
3-year CAGR-5.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
164K USD
Year-over-year change
+100.0%
4-year CAGR
+45.1%

Cost of Revenue vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +58.1% is the 2nd highest of 8, against a peer median of +2.8%.
  • Cost of revenue amounts to 291.2% of revenue for SERA, versus a peer median of 87.6%.
SERA Competitors
Cost of Revenue for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
APYXApyx Medical CorporationLTM Mar 2026$37.86M USD+65.4%+30.0%67.7%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$30.12M USD+8.2%+0.4%87.6%
LUCDLucid Diagnostics Inc.LTM Mar 2026$7.19M USD+2.8%+27.8%140.0%
STSSSkyAI, Inc.LTM Mar 2026$820.02K USD+29.4%-1.9%206.6%
SERASera Prognostics, Inc.LTM Mar 2026$166K USD+58.1%-5.3%291.2%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$129K USD———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$119.31K CAD-26.6%-38.5%—
SRZNSurrozen, Inc.LTM Mar 2026$65K USD-83.2%-45.2%0.9%
HURATuHURA Biosciences, Inc.LTM Mar 2026$23.47K USD-63.1%——
Peer median (excluding SERA) —+2.8%-0.8%87.6%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue82K268K306K77K81K
Cost of Revenue37K193K210K82K164K
Gross Profit45K75K96K(5K)(83K)
Gross Margin54.9%28.0%31.4%-6.5%-102.5%
Research & Development11.02M14.24M15.23M14.73M13.17M
Selling, General & Admin24.42M31.48M24.69M21.9M23.25M
Operating Expenses35.44M45.73M39.92M36.63M36.42M
Depreciation & Amortization659K756K900K833K940K
EBITDA(33.6M)(43.37M)(35.29M)(32.04M)(30.98M)
EBITDA Margin-40980.5%-16182.5%-11531.7%-41606.5%-38245.7%
Operating Income(35.4M)(45.65M)(39.82M)(36.64M)(36.5M)
Operating Margin-43164.6%-17034.3%-13013.4%-47577.9%-45066.7%
Interest Income145K456K1.64M2.75M4.59M
Interest Expense746K61K55K28K9K
Other Income / Expenses386K1.47M3.58M3.74M4.58M
Income Before Tax(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Pre-Tax Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
Income Tax Expense00000
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Net Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
EPS (Basic)(1.18)(1.43)(1.16)(0.99)(0.67)
EPS (Diluted)(1.18)(1.43)(1.16)(0.99)(0.67)
Weighted Avg Shares30.77M30.94M31.2M33.16M47.66M
Weighted Avg Shares (Diluted)30.77M30.94M31.2M33.16M47.66M

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.